Document is current
Any future updates will be listed below
-
Authors
Seehawer, Marco http://orcid.org/0000-0003-0440-6967
Li, Zheqi http://orcid.org/0000-0003-1213-640X
Nishida, Jun http://orcid.org/0000-0001-5098-9361
Foidart, Pierre
Reiter, Andrew H. http://orcid.org/0000-0003-1406-4913
Rojas-Jimenez, Ernesto
Goyette, Marie-Anne http://orcid.org/0000-0003-3199-2252
Yan, Pengze
Raval, Shaunak
Munoz Gomez, Miguel
Cejas, Paloma http://orcid.org/0000-0002-2090-7748
Long, Henry W. http://orcid.org/0000-0001-6849-6629
Papanastasiou, Malvina http://orcid.org/0000-0003-3378-6612
Polyak, Kornelia http://orcid.org/0000-0002-5964-0382
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA197623, CA250959)
European Molecular Biology Organization (NA)
Canadian Institute for Advanced Research (NA)
- License Information
-
More Information
Article History
Received: 15 August 2023
Accepted: 29 May 2024
First Online: 26 June 2024
Competing interests
: K.P. serves on the Scientific Advisory Board of and holds equity options in IDEAYA Biosciences and Scorpion Therapeutics. K.P. and H.W.L. receive sponsored research funding through the Dana-Farber Cancer Institute from Novartis. The remaining authors declare no competing interests.
